Pharmacokinetics of nelfinavir in HIV-1-infected pregnant and nonpregnant women.
about
Pregnancy-Associated Changes in Pharmacokinetics: A Systematic ReviewImplications of gender and pregnancy for antiretroviral drug dosingPharmacokinetics and safety of nelfinavir when used in combination with zidovudine and lamivudine in HIV-infected pregnant women: Pediatric AIDS Clinical Trials Group (PACTG) Protocol 353.Effects of highly active antiretroviral therapy duration and regimen on risk for mother-to-child transmission of HIV in Johannesburg, South AfricaProtecting the fetus against HIV infection: a systematic review of placental transfer of antiretrovirals.Alteration in cytochrome P450 3A4 activity as measured by a urine cortisol assay in HIV-1-infected pregnant women and relationship to antiretroviral pharmacokinetics.Atazanavir pharmacokinetics with and without tenofovir during pregnancyClinical therapeutics in pregnancy.Selection of HIV resistance associated with antiretroviral therapy initiated due to pregnancy and suspended postpartum.Pharmacologic and nonpharmacologic options for the management of HIV infection during pregnancy.Factors associated with HIV RNA levels in pregnant women on non-suppressive highly active antiretroviral therapy at conception.Pharmacokinetic modelling of the placental transfer of nelfinavir and its M8 metabolite: a population study using 75 maternal-cord plasma samples.Pharmacokinetics of tacrolimus during pregnancyPharmacokinetics of drugs in pregnancy.Interpreting tacrolimus concentrations during pregnancy and postpartum.Pharmacokinetics and therapeutic drug monitoring of antiretrovirals in pregnant womenSteady-state pharmacokinetics, cord blood concentrations, and safety of ritonavir-boosted fosamprenavir in pregnancy.Genital tract, cord blood, and amniotic fluid exposures of seven antiretroviral drugs during and after pregnancy in human immunodeficiency virus type 1-infected women.Practical therapeutic drug management in HIV-infected patients: use of population pharmacokinetic models supplemented by individualized Bayesian dose optimizationPharmacokinetics of new 625 mg nelfinavir formulation during pregnancy and postpartum.Therapeutic drug monitoring in highly active antiretroviral therapy.Pharmacokinetic optimization of antiretroviral therapy in pregnancy.HIV protease inhibitors in pregnancy : pharmacology and clinical use.Therapeutic drug monitoring of antiretroviral drugs in HIV-infected patients.Steady-state nevirapine plasma concentrations are influenced by pregnancy.The application of physiologically-based pharmacokinetic modelling to assess the impact of antiretroviral-mediated drug-drug interactions on piperaquine antimalarial therapy during pregnancy.Pharmacokinetic studies in pregnant women.Time to undetectable viral load after highly active antiretroviral therapy initiation among HIV-infected pregnant women.
P2860
Q28109657-ED14D119-D731-4303-9528-A35400E56BB2Q33584069-A2576B77-16E3-4595-B898-96B41E59B8DAQ33705707-F068B8A0-2126-4878-86CC-A4D3C0EB6ABCQ33893057-A34DBAA7-E5EF-4BAB-BE72-BBBBCDD6C02DQ34429204-6A5CA728-DACC-447F-B002-F2A47813CAF6Q35060812-43084483-6DB7-4BCB-8E37-DD83029DF643Q35074548-D0607A57-FB91-4A47-9BC7-77E8F4285E46Q35113890-090A9546-029D-40F4-8F47-945724BB9013Q35388475-B275CA68-7934-41DB-9362-15E24C95ACE3Q35557216-58B92013-6982-4601-8107-EF61E188013EQ36193307-B9AF6F91-094B-4E7A-8754-CA3AC8B34B27Q36388061-2EEE1E92-56F8-4677-A30F-9ABCF5F9E59CQ36400412-C541C0BB-97E5-474E-9FF9-AA927FD813A9Q36734138-C7412020-D103-43FC-B873-6F5566025B69Q36799909-70105FCA-554D-4CDA-A9A3-A02BF9030F50Q36803454-A84F92DA-B820-4EF8-8D1E-51344D06F148Q36930395-98579552-326A-4B3B-BBFE-B014F65573AFQ37204271-EF16730F-E023-47A2-BDC7-E953A5E19707Q37298637-1EA5F103-B065-46B5-BB19-D1ED348EEE4DQ37319793-21E5EE87-E781-46E6-9366-6D07821DE499Q37720765-329436A8-354D-4918-B11D-78BCD9753176Q38047214-9B61A308-9253-4EC0-9B60-84904A7B571BQ38081072-00B7801C-FDA6-4767-89B8-5620D8D92938Q38954109-7D1939C3-131B-4B26-A5F0-3C15C16BBB5EQ39298708-2F892BE8-9771-44D6-ACB9-8AAC973CFE58Q40133890-0EF086CE-3F85-4C4C-A61A-93C95DD3B1F6Q42007783-928508D9-E894-494C-93C9-1B2388841F28Q45200184-EF1BE3E9-FCBF-4D96-9C3F-5779711492B1
P2860
Pharmacokinetics of nelfinavir in HIV-1-infected pregnant and nonpregnant women.
description
2006 nî lūn-bûn
@nan
2006年の論文
@ja
2006年論文
@yue
2006年論文
@zh-hant
2006年論文
@zh-hk
2006年論文
@zh-mo
2006年論文
@zh-tw
2006年论文
@wuu
2006年论文
@zh
2006年论文
@zh-cn
name
Pharmacokinetics of nelfinavir in HIV-1-infected pregnant and nonpregnant women.
@ast
Pharmacokinetics of nelfinavir in HIV-1-infected pregnant and nonpregnant women.
@en
type
label
Pharmacokinetics of nelfinavir in HIV-1-infected pregnant and nonpregnant women.
@ast
Pharmacokinetics of nelfinavir in HIV-1-infected pregnant and nonpregnant women.
@en
prefLabel
Pharmacokinetics of nelfinavir in HIV-1-infected pregnant and nonpregnant women.
@ast
Pharmacokinetics of nelfinavir in HIV-1-infected pregnant and nonpregnant women.
@en
P2093
P2860
P50
P1476
Pharmacokinetics of nelfinavir in HIV-1-infected pregnant and nonpregnant women.
@en
P2093
A Molinari
A degli Antoni
E Tamburrini
M F Pirillo
P2860
P304
P356
10.1111/J.1365-2125.2006.02669.X
P407
P577
2006-09-01T00:00:00Z